Dr. Paul McKenzie has been appointed as Chief Executive Officer (CEO) and Managing Director of CSL, and will take on the role in March.
Dr. McKenzie will succeed Paul Perreault, who will retire after 10 years in the role and more than 25 years with the company.
Currently serving as CSL’s Chief Operating Officer (COO), Dr McKenzie will immediately join the Board of Directors as an Executive Director and will become CEO and Managing Director on March 6, 2023.
Perreault will step down as CEO and from the CSL Board of Directors on the same date; but remain with the company as strategic advisor to assist in the transition until September.
Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation.
Since joining CSL as COO in 2019, Dr McKenzie has been accountable for optimising CSL’s operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses. He transformed CSL’s global end-to-end operations, advanced CSL Seqirus’ differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels.
Prior to joining CSL, Dr McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.
He was elected to the National Academy of Engineering in 2020. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. Paul holds a B.S. in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering from Carnegie Mellon University.
CSL – which includes three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides products to patients in more than 100 countries and employs 30,000 people.